IDH1 and astrocytoma (excluding glioblastoma): To further investigate the safety and immunogenicity of the IDH1-specific vaccine in humans, a multicenter phase I trial was conducted on 32 patients with newly diagnosed grade 3 and 4 IDH1(R132H) + astrocytoma.